Works by Lu, Yen-Shen

Results: 64
    1

    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

    Published in:
    Nature Communications, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41467-025-59210-6
    By:
    • Hu, Xichun;
    • Zhang, Qingyuan;
    • Sun, Tao;
    • Xiong, Huihua;
    • Li, Wei;
    • Teng, Yuee;
    • Lu, Yen-Shen;
    • Tseng, Ling-Ming;
    • Yan, Min;
    • Li, Hongsheng;
    • Pang, Danmei;
    • -Chen, Shin-Cheh;
    • Chen, Wenyan;
    • Jiang, Ou;
    • Wang, Jingfen;
    • Wu, Xinhong;
    • Wang, Xian;
    • Zang, Aimin;
    • Wang, Xiaojia;
    • Collins, Julie M.
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).

    Published in:
    Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920943065
    By:
    • Harbeck, Nadia;
    • Franke, Fabio;
    • Villanueva-Vazquez, Rafael;
    • Lu, Yen-Shen;
    • Tripathy, Debu;
    • Chow, Louis;
    • Babu, Govind K;
    • Im, Young-Hyuck;
    • Chandiwana, David;
    • Gaur, Anil;
    • Lanoue, Brad;
    • Rodriguez-Lorenc, Karen;
    • Bardia, Aditya
    Publication type:
    Article
    12
    13
    14

    Anti-tumor efficacy of a bevacizumab preconditioning followed by etoposide and cisplatin regimen in human epidermal growth factor receptor-2-positive breast cancer brain metastasis refractory to whole brain radiotherapy.

    Published in:
    Journal of Cancer Research & Practice, 2023, v. 10, n. 1, p. 11, doi. 10.4103/ejcrp.eJCRP-D-23-00001
    By:
    • Chen, Tom;
    • Lin, Ching-Hung;
    • Yeh, Dah-Cherng;
    • Tseng, Ling-Ming;
    • Rau, Kun-Ming;
    • Chen, Bang-Bin;
    • Chao, Ta-Chung;
    • Huang, Shu-Min;
    • Chang, Dwan-Ying;
    • Chen, I-Chun;
    • Cheng, Ann-Lii;
    • Lu, Yen-Shen
    Publication type:
    Article
    15
    16
    17
    18
    19
    20

    HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.

    Published in:
    2022
    By:
    • Tan, Ryan Shea Ying Cong;
    • Ong, Whee Sze;
    • Lee, Kyung-Hun;
    • Lim, Abner Herbert;
    • Park, Seri;
    • Park, Yeon Hee;
    • Lin, Ching-Hung;
    • Lu, Yen-Shen;
    • Ono, Makiko;
    • Ueno, Takayuki;
    • Naito, Yoichi;
    • Onishi, Tatsuya;
    • Lim, Geok-Hoon;
    • Tan, Su-Ming;
    • Lee, Han-Byoel;
    • Ryu, Han Suk;
    • Han, Wonshik;
    • Tan, Veronique Kiak Mien;
    • Wong, Fuh-Yong;
    • Im, Seock-Ah
    Publication type:
    journal article
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    SGLT2 inhibition improves PI3Kα inhibitor–induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.

    Published in:
    Breast Cancer Research & Treatment, 2024, v. 208, n. 1, p. 111, doi. 10.1007/s10549-024-07405-8
    By:
    • Borrego, Manuel Ruiz;
    • Lu, Yen-Shen;
    • Reyes-Cosmelli, Felipe;
    • Park, Yeon Hee;
    • Yamashita, Toshinari;
    • Chiu, Joanne;
    • Airoldi, Mario;
    • Turner, Nicholas;
    • Fein, Luis;
    • Ghaznawi, Farhat;
    • Singh, Jyotika;
    • Pantoja, Kristyn;
    • Schnell, Christian;
    • Akdere, Murat;
    • Chia, Stephen
    Publication type:
    Article
    31
    32
    33
    34
    35

    A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.

    Published in:
    NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00684-w
    By:
    • Noguchi, Emi;
    • Yamanaka, Takashi;
    • Mukai, Hirofumi;
    • Yamamoto, Naohito;
    • Chung, Chi-Feng;
    • Lu, Yen-Shen;
    • Chang, Dwan-Ying;
    • Sohn, Joohyuk;
    • Kim, Gun Min;
    • Lee, Kyung-Hun;
    • Lee, Soo-Chin;
    • Iwasa, Tsutomu;
    • Iwata, Hiroji;
    • Watanabe, Kenichi;
    • Jung, Kyung Hae;
    • Tanabe, Yuko;
    • Kang, Seok Yun;
    • Yasojima, Hiroyuki;
    • Aogi, Kenjiro;
    • Tokunaga, Eriko
    Publication type:
    Article
    36

    Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis.

    Published in:
    Cancer Medicine, 2024, v. 13, n. 14, p. 1, doi. 10.1002/cam4.70005
    By:
    • Yang, Ming‐Han;
    • Huang, Chiun‐Sheng;
    • Chang, Dwan‐Ying;
    • Hu, Fu‐Chang;
    • Huang, Shu‐Min;
    • Huang, Po‐Hsiang;
    • Chen, I‐Chun;
    • Chen, Tom Wei‐Wu;
    • Lin, Ching‐Hung;
    • Lu, Yen‐Shen
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43

    A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.

    Published in:
    2021
    By:
    • Schmid, Peter;
    • Sablin, Marie-Paule;
    • Bergh, Jonas;
    • Im, Seock-Ah;
    • Lu, Yen-Shen;
    • Martínez, Noelia;
    • Neven, Patrick;
    • Lee, Keun Seok;
    • Morales, Serafín;
    • Pérez-Fidalgo, J. Alejandro;
    • Adamson, Douglas;
    • Gonçalves, Anthony;
    • Prat, Aleix;
    • Jerusalem, Guy;
    • Schlieker, Laura;
    • Espadero, Rosa-Maria;
    • Bogenrieder, Thomas;
    • Huang, Dennis Chin-Lun;
    • Crown, John;
    • Cortés, Javier
    Publication type:
    journal article
    44
    45
    46
    47
    48
    49
    50